Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 11.02 -4.42% -0.51
ACOR closed down 4.42 percent on Friday, May 17, 2019, on 1.19 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ACOR trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Shooting Star Candlestick Bearish -4.42%
1,2,3 Retracement Bearish Bearish Swing Setup -4.42%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.42%
Up 3 Days in a Row Strength -4.42%
Crossed Above 20 DMA Bullish -2.30%
NR7 Range Contraction -2.30%
Inside Day Range Contraction -0.99%
Fell Below 20 DMA Bearish 1.57%
Down 3 Days in a Row Weakness 1.57%

Older signals for ACOR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Chemistry Health Biopharmaceutical Antibodies Autoimmune Diseases Clinical Trial Multiple Sclerosis Central Nervous System Disorders Heart Failure Spinal Cord Injury Treatment Of Heart Failure
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 36.35
52 Week Low 9.58
Average Volume 779,906
200-Day Moving Average 17.4421
50-Day Moving Average 12.392
20-Day Moving Average 11.201
10-Day Moving Average 11.442
Average True Range 0.6375
ADX 35.9
+DI 17.3701
-DI 26.2686
Chandelier Exit (Long, 3 ATRs ) 10.2375
Chandelier Exit (Short, 3 ATRs ) 11.4925
Upper Bollinger Band 12.1535
Lower Bollinger Band 10.2485
Percent B (%b) 0.4
BandWidth 17.00741
MACD Line -0.2911
MACD Signal Line -0.3725
MACD Histogram 0.0813
Fundamentals Value
Market Cap 513.04 Million
Num Shares 46.6 Million
EPS -0.94
Price-to-Earnings (P/E) Ratio -11.72
Price-to-Sales 2.27
Price-to-Book 1.76
PEG Ratio 0.51
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.21
Resistance 3 (R3) 12.32 12.04 12.01
Resistance 2 (R2) 12.04 11.74 11.98 11.94
Resistance 1 (R1) 11.53 11.55 11.39 11.42 11.88
Pivot Point 11.25 11.25 11.18 11.19 11.25
Support 1 (S1) 10.74 10.95 10.60 10.63 10.16
Support 2 (S2) 10.46 10.76 10.40 10.10
Support 3 (S3) 9.95 10.46 10.03
Support 4 (S4) 9.84